Company Filing History:
Years Active: 2014
Title: Ramon Eritja: Innovator in Oligonucleotide-Based Therapies
Introduction
Ramon Eritja is a notable inventor based in Barcelona, Spain. He has made significant contributions to the field of oligonucleotide-based therapies, particularly through his innovative work on novel oligomer analogues.
Latest Patents
Eritja holds a patent for "Sphingosine-bound siRNA." This invention relates to novel oligomer analogues and their use in oligonucleotide-based therapies. More specifically, it concerns oligonucleotides carrying lipid molecules and their potential use as inhibitors of gene expression. He has 1 patent to his name.
Career Highlights
Ramon Eritja is associated with Sylentis S.A.U., a company focused on developing innovative therapies. His work has been instrumental in advancing the understanding and application of oligonucleotide technologies.
Collaborations
Eritja has collaborated with talented professionals in his field, including Ana Isabel Jimenez and Gema Panizo. Their combined expertise contributes to the innovative environment at Sylentis.
Conclusion
Ramon Eritja's contributions to the field of oligonucleotide-based therapies highlight his role as a key innovator. His work continues to pave the way for advancements in gene expression inhibition.